A share price of Biogen Inc [BIIB] is currently trading at $142.65, up 0.66%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BIIB shares have lost -0.56% over the last week, with a monthly amount drifted -0.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on February 11, 2025, when Bernstein initiated its Mkt Perform rating and assigned the stock a price target of $160. Previously, Piper Sandler downgraded its rating to Neutral on January 02, 2025, and dropped its price target to $138. On December 20, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $164 on the stock. Stifel downgraded its rating to a Hold but stick to its price target of $175 on December 16, 2024. Jefferies downgraded its rating to Hold for this stock on December 09, 2024, and downed its price target to $180. In a note dated November 18, 2024, Needham downgraded an Hold rating on this stock.
Biogen Inc experienced fluctuations in its stock price throughout the past year between $128.51 and $238.00. Currently, Wall Street analysts expect the stock to reach $233.92 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $142.65 at the most recent close of the market. An investor can expect a potential return of 63.98% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
Trailing Twelve Months sales for Biogen Inc [NASDAQ:BIIB] were 9.27B which represents 1.66% growth. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.1 and Total Capital is 0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 140.11 points at the first support level, and at 137.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 146.59, and for the 2nd resistance point, it is at 150.54.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Biogen Inc [NASDAQ:BIIB] is 1.35. Further, the Quick Ratio stands at 0.90, while the Cash Ratio is 0.43. Considering the valuation of this stock, the price to sales ratio is 2.25, the price to book ratio is 1.24 and price to earnings (TTM) ratio is 12.76.
Transactions by insiders
Recent insider trading involved Singhal Priya, Head of Development, that happened on Dec 09 ’24 when 110.0 shares were sold. Officer, Singhal Priya completed a deal on Dec 09 ’24 to buy 110.0 shares. Meanwhile, Head of Development Singhal Priya sold 431.0 shares on Sep 03 ’24.
